Compare American International Group Inc (AIG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Novo Nordisk A/S — how do they compare? American International Group Inc trades at $76.56 (market cap $40.42B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.1× American International Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| AIG | NVO | |
|---|---|---|
Market Cap | $40.42B | $207.85B |
Sector | Financials | Health |
52-Week High | $86.59 | $63.98 |
52-Week Low | $71.89 | $35.29 |
Enterprise Value | $48.06B | $222.55B |
Dividend Yield | 2.59% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.42, down 1.53% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with $2.11 EPS versus $1.89 expected, driven by robust underwriting income. Revenue for 2025 was $26.77B with net income of $3.10B, yielding an 11.12% net margin. The stock carries a P/E of 14.11 and a consensus analyst price target of $89.00, suggesting potential upside from current levels.
The outlook for AIG is mixed; solid earnings performance and a diversified insurance portfolio support growth, but competitive pricing pressure and investment income headwinds pose risks. With 39% of analysts rating it a Buy, the stock appears undervalued relative to its price target, though near-term catalysts may be limited amid broader market volatility.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
